Equity
€14.4m ▲ 8.3%
DIDAK INJECTION has made a profit in every financial year since 2007.
DIDAK INJECTION
Lifetime
19 annual accounts with figures on one time axis, 40 filings since 1986peak €62.3m (2021)
€43.5m▲ 11.0%
peak €4.7m (2021)
€2.3m▲ 7.5%
peak €14.4m (2021)
€14.4m▲ 8.3%
€10.8m▼ 7.1%
peak 100.7 FTE (2022)
80.6 FTE▼ 7.4%
Board9 names since 2018
3 directorsVANDEPUTTE-VALCKE and 2 others
Owners4 names in the annual accounts
33.36%VANDEPUTTE - VALCKE and 1 other
Documentsfilings and deeds
29-06-202632 days before the deadline
2025financial year
Dividend €1.2mCash from €657,157 to €226,769
Key points
from the 2025 annual accountsStaff
82 employees on 31-12-2025
In 2025, 8 people joined and 13 left. On top of that, 41 agency workers worked there on average.
Filings
40 annual accounts since 1986
Six of the last ten came late. The 2019 accounts came latest: 31 days after the end of the period.
Board
1 joined · 1 left
Board changed. Latest change 16-07-2026 · 3 in office.
Position in the sector
€2.3m
Higher net result than 83% of companies in rubber and plastics. Sector median €154,622 · 230 companies.
Public support
€252,223 awarded from 2022 to 2025
Flemish support, mostly Ontwikkelingsproject.
Checked score
92
Excellent
Financially stronger than 59% of medium-sized companies in rubber and plastics (NACE 22)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.2% across 77 companies (NACE 22, medium-sized).
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.2%
01-2025: 0.2%● unchanged vs 12-2024
02-2025: 0.2%● unchanged vs 01-2025
03-2025: 0.2%● unchanged vs 02-2025
04-2025: 0.2%● unchanged vs 03-2025
05-2025: 0.2%● unchanged vs 04-2025
06-2025: 0.2%● unchanged vs 05-2025
07-2025: 0.2%● unchanged vs 06-2025
08-2025: 0.4%▲ +0.2 percentage points vs 07-2025
09-2025: 0.1%▼ -0.3 percentage points vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026lowest value
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.1%● unchanged vs 03-2026
05-2026: 0.2%▲ +0.1 percentage points vs 04-2026
06-2026: 0.2%● unchanged vs 05-2026
07-2026: 0.2%● unchanged vs 06-2026
08-2026: 0.3%▲ +0.1 percentage points vs 07-2026
09-2026: 0.4%▲ +0.1 percentage points vs 08-2026highest value
10-2026: 0.2%▼ -0.2 percentage points vs 09-2026
11-2026: 0.2%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
raises risk
Liquidity: current ratio 1.22, cash €226,769, halved
lowers risk
Founded in 1986
Equity €14.4m (57.0% of total assets)
Profit of €2.3m (financial year 2025)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 22, medium-sized). It does better than 58% of them on solvency, 28% on liquidity, 74% on profitability and 77% on growth.
The bankruptcy probability was computed on 07-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 1,579 companies had the same profile as DIDAK INJECTION has now. Each dot stands for 4 companies, two years later.
96.6%
were still trading
3.2%
stopped another way
0.1%
went bankrupt
That fits the bankruptcy probability of DIDAK INJECTION itself: 0.2% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,579 companies, not a prediction for DIDAK INJECTION. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €1,300,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.22 (1.15 in 2024), below the usual 1.5. Short-term debt is 41.5% and cash 0.9% of total assets. 43% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
lowers risk · Growing equity
Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year €14.4m
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-06-2026, 32 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
32 days early
2024
29 days late
2023
33 days early
2022
4 days early
2021
5 days late
2020
31 days late
2019
31 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 4 days after the deadline. In the sector (NACE 22), the median for financial year 2024 was 14 days before the deadline, and 34% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 27 July (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
08-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- ECNOEL 33.36%score 91equity €18.3m (2025) · 30-06-2022 annual accounts of ECNOEL
- VANDEPUTTE - VALCKE 33.36%equity €4.2m (2025) · 30-09-2025 annual accounts of VANDEPUTTE - VALCKE
- HUNTER EN COLMAN 33.27%score 88equity €627,431 (2025) · 30-06-2025 annual accounts of HUNTER EN COLMAN
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0428125831
4 directors appointed, 2 resignations
Change of role: SALDEC, from director to class B director · Resignations: HUNTER & COLMAN and VANDEPUTTE Peter · Permanent representatives: DECEUNINCK Alexander, DECEUNINCK Arnold Benari, VANDEPUTTE Peter and VAN HEMELDONCK Emiel · General meeting of 24-01-2024 · Gazette deed
Reappointment: SALDEC (director)
Permanent representative: Alexander DECEUNINCK · General meeting of 30-04-2020 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| DIDAK INJECTION Grobbendonk | €43.5m | 8.1% | 57.0% | 80.6 |
| METHODE ELECTRONICS BELGIUM Lontzen | €36.9m | 15.8% | 76.9% | 99.4 |
| ANZIPLAST Izegem | €30.0m | 7.1% | 43.2% | 111.9 |
| GAMMA-WOPLA Mouscron | €41.0m | 6.9% | 60.4% | 71 |
| HUBERT DE BACKER Temse | €40.3m | 3.4% | 78.1% | 155.9 |
| ORAC Ostend | €59.6m | 7.0% | 21.6% | 76.6 |
| REMOTEC Deinze | €31.3m | 8.5% | 11.6% | 74.3 |
Grey: the largest companies of the sector (rubber and plastics (NACE 22)), without their names. Blue: the sector peers from the table.
These companies have the same main activity as DIDAK INJECTION: manufacture of rubber and plastic products (NACE 22260). They are comparable in size and age: total assets between €11m and €37m, founded between 1970 and 1997.
Official details
Source: KBO- Status
- Active since 02-01-1986Normal situation
- Activity
- Manufacture of rubber and plastic productsNACE 22260and 1 other
- Joint committees
- 207White-collar workers in the chemical industry
- 116Chemical industry · annual accounts 2025
- Establishment unit
- 2.028.517.2502280 Grobbendonk, since 01-01-1986
- Financial year end
- 31 December
- Peppol
- Reachable since 05-01-2026
Annual accounts 2025
- €25.3m▲ 1.1%
- Employeeson 31-12-2025
- 82▼ 5.7%
- Filing
- Filed on 29-06-2026, 32 days before the end of the filing period
Insights on DIDAK INJECTION
DIDAK INJECTION has existed since 1986. Turnover grew from €31.3m in 2007 to €43.5m in 2025.
In February 2024, three directors stepped down.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about DIDAK INJECTION
- What is the company number of DIDAK INJECTION?
- The company number of DIDAK INJECTION is 0428.125.831. The VAT number is the same number with BE in front: BE 0428.125.831.
- Where is DIDAK INJECTION based?
- The registered office is at Industrieweg 1, 2280 Grobbendonk.Company details
- What does DIDAK INJECTION do?
- According to the KBO register, the main activity is manufacture of rubber and plastic products (NACE 22260).
- What is the legal form of DIDAK INJECTION?
- DIDAK INJECTION is a public limited company (NV).
- When was DIDAK INJECTION founded?
- DIDAK INJECTION was founded on 02-01-1986.
- Is DIDAK INJECTION still active?
- Yes, DIDAK INJECTION is an active enterprise in the KBO register.
- How many employees does DIDAK INJECTION have?
- DIDAK INJECTION had an average of 80.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does DIDAK INJECTION fall under?
- In its 2025 annual accounts, DIDAK INJECTION states joint committees 207 (White-collar workers in the chemical industry) and 116 (Chemical industry).
- What is the turnover of DIDAK INJECTION?
- The turnover of DIDAK INJECTION was €43.5m in financial year 2025, according to the filed annual accounts.
- Is DIDAK INJECTION profitable?
- In financial year 2025, DIDAK INJECTION made a profit of €2.3m.
- Where can I find the annual accounts of DIDAK INJECTION?
- DIDAK INJECTION filed 40 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of DIDAK INJECTION due?
- DIDAK INJECTION must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies
See how customers, suppliers and banks see your own company and what to improve first.